Ahmedabad, India

Dipti Mehta

This inventor holds 1 USPTO granted patent. Top assignee: Cadila Healthcare Limited. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dipti Mehta. Retrieved from https://idiyas.com/inventor/dipti-mehta-if01r2h1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dipti Mehta: Innovator in Antibody Research

Introduction

Dipti Mehta is a prominent inventor based in Ahmedabad, India. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies. Her work is recognized for its potential impact on medical treatments and therapies.

Latest Patents

Dipti holds a patent for "Antibodies to Human Programmed Death Receptor PD-1." This innovation is crucial in the ongoing research and development of cancer therapies, as PD-1 is a key target in immunotherapy.

Career Highlights

Dipti Mehta is associated with Cadila Healthcare Limited, a leading pharmaceutical company in India. Her role at the company has allowed her to work on groundbreaking research that aims to improve patient outcomes through innovative treatments.

Collaborations

Some of her notable coworkers include Pankaj Kalita and Hardik Pandya. Their collaborative efforts contribute to the advancement of research and development within the company.

Conclusion

Dipti Mehta's work exemplifies the spirit of innovation in the field of biotechnology. Her contributions, particularly in antibody research, are paving the way for future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…